Trials / Completed
CompletedNCT01272999
Impact of Prevnar 13 on Ear Infections in Children
POSTMARKETING OBSERVATIONAL STUDY OF THE IMPACT OF PREVNAR 13 (PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE) ON OTITIS MEDIA IN CHILDREN
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 391 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
Prevnar (7 valent pneumococcal conjugate vaccine \[7vPnC\]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar. It is expected that the effectiveness of Prevnar 13 against ear infections in children will be similar to that observed following Prevnar. Pfizer has committed to conduct a postmarketing study of the impact of Prevnar 13 in reducing ear infections among children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | Non interventional |
Timeline
- Start date
- 2010-05-21
- Primary completion
- 2013-12-19
- Completion
- 2013-12-19
- First posted
- 2011-01-10
- Last updated
- 2023-05-23
- Results posted
- 2020-11-10
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01272999. Inclusion in this directory is not an endorsement.